What question did this study set out to answer?

To investigate the expression of interleukin-40 (IL-40) in rheumatoid arthritis, its correlation with clinical markers, and its response to B cell depletion therapy.

October 21, 2021Frontiers in ImmunologyOpen Access

IL-40: A New B Cell-Associated Cytokine Up-Regulated in Rheumatoid Arthritis Decreases Following the Rituximab Therapy and Correlates With Disease Activity, Autoantibodies, and NETosis

View Full Paper

Ask AI

Bookmark

Authors

ANAdéla NavrátilováCharles University LCLucie Andrés CerezoCharles University HHHana HulejováInstitute of Rheumatology

Discussion

Member takes

Implication

Translational study reveals elevated IL-40 in rheumatoid arthritis decreases after rituximab therapy, suggesting its active role in driving synovial inflammation.

Key Points

To investigate the expression of interleukin-40 (IL-40) in rheumatoid arthritis, its correlation with clinical markers, and its response to B cell depletion therapy.
Evaluated IL-40 expression levels in patients with rheumatoid arthritis before and after B cell-depleting rituximab therapy.
Assessed correlations between IL-40, disease activity, autoantibodies, chemokines, and markers of NETosis.
Treated cultured synovial fibroblasts with IL-40 in vitro to quantify chemokine and matrix metalloproteinase-13 (MMP-13) secretion.
IL-40 levels are significantly elevated in rheumatoid arthritis and decrease following B cell depletion with rituximab.
Circulating IL-40 correlates positively with autoantibodies, chemokines, and markers indicative of NETosis.
IL-40 stimulates the secretion of chemokines and MMP-13 in synovial fibroblasts, promoting inflammation and joint tissue destruction.

Cite This Study

Navrátilová et al. (2021) studied this question.

synapsesocial.com/papers/69dea604077ec87fd1e93b04 https://doi.org/10.3389/fimmu.2021.745523

View Full Paper

Ask AI

Bookmark

Implication

Translational study reveals elevated IL-40 in rheumatoid arthritis decreases after rituximab therapy, suggesting its active role in driving synovial inflammation.

IL-40: A New B Cell-Associated Cytokine Up-Regulated in Rheumatoid Arthritis Decreases Following the Rituximab Therapy and Correlates With Disease Activity, Autoantibodies, and NETosis

Discussion

Member takes

Implication

Key Points

Cite This Study

IL-40: A New B Cell-Associated Cytokine Up-Regulated in Rheumatoid Arthritis Decreases Following the Rituximab Therapy and Correlates With Disease Activity, Autoantibodies, and NETosis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider